Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D3S-001 in KRAS p.G12C-mutated advanced solid tumors
2023-508517-16-00Phase 2Authorised
- Sponsor
- D3 Bio
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of elisrasib in Nonhematologic neoplasms (4 arms), sponsored by D3 Bio. Primary endpoints: Treatment-emergent adverse events and treatment-related adverse events, Clinical safety assessments and 2 more. Planned start Apr 2024; status: authorised.
02
Drugs
elisrasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-508517-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508517-16-00.